Andra AP-fonden’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.9M Buy
211,000
+70,900
+51% +$4.18M 0.14% 175
2026
Q2
$7.86M Sell
140,100
-37,400
-21% -$1.95M 0.09% 235
2026
Q1
$8.51M Buy
+177,500
New +$7.77M 0.1% 223
2024
Q1
– Sell
-198,700
Closed -$5.58M – 428
2023
Q4
$5.58M Buy
198,700
+40,500
+26% +$1.11M 0.3% 158
2023
Q3
$4.29M Buy
158,200
+5,500
+4% +$163K 0.25% 192
2023
Q2
$4.69M Buy
152,700
+42,100
+38% +$1.43M 0.12% 405
2023
Q1
$3.98M Sell
110,600
-41,200
-27% -$1.53M 0.1% 422
2022
Q4
$6M Sell
151,800
-18,400
-11% -$768K 0.18% 251
2022
Q3
$6.84M Buy
170,200
+30,900
+22% +$1.32M 0.22% 175
2022
Q2
$5.86M Buy
+139,300
New +$5.71M 0.17% 272
2021
Q4
$5.67M Sell
142,300
-16,300
-10% -$633K 0.12% 391
2021
Q3
$5.73M Buy
158,600
+28,500
+22% +$1.11M 0.12% 389
2021
Q2
$5.33M Buy
130,100
+29,800
+30% +$1.27M 0.11% 426
2021
Q1
$4.38M Sell
100,300
-16,500
-14% -$782K 0.1% 459
2020
Q4
$5.85M Buy
+116,800
New +$4.96M 0.13% 392

Other funds holding RPRX

Andra AP-fonden's RPRX Position: Q3 2026 in Review

Andra AP-fonden increased its Royalty Pharma (RPRX) stake by 51% in Q3 2026, buying an estimated $4.18M and bringing the position to 211,000 shares worth $11.9M. The position accounts for 0.14% of the portfolio, ranked #175.

Andra AP-fonden first reported a position in RPRX in Q4 2020 and has held it in 15 quarters since. 705 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Andra AP-fonden held 211,000 shares of Royalty Pharma worth $11.9M as of Q3 2026.
  • Andra AP-fonden bought 70,900 Royalty Pharma shares in Q3 2026, an estimated $4.18M.
  • Royalty Pharma made up 0.14% of Andra AP-fonden's portfolio in Q3 2026, its #175 holding.
  • Andra AP-fonden first reported a position in Royalty Pharma in Q4 2020 and has held it in 15 quarters since.
  • 705 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Andra AP-fonden's 13F filing for Q3 2026, filed 13 Nov 2026.